Events & Ideas

Pinney Associates, whose expert team anticipates pharmaceutical and consumer healthcare companies’ scientific and policy challenges and guides them toward regulatory and marketplace success, is pleased to announce its new leadership team. Joe Gitchell recently assumed the role of CEO, Lucy Owen is our new President, Judy Ashworth has been promoted to Senior Vice President, and… Read More

August 3-5, 2023 | Washington, DC Caitlyn Durgin will be attending. VIEW CONFERENCE Poster: Within-subject Comparison of Inter-individual Variations in Opioid-induced Effects

Durgin C, Huhn A, Bergeria C, Finan P, Campbell C, Antoine D, Dunn K. Inter-individual differences in sensitivity to opioids may explain different opioid risk profiles, but to date has only been evaluated in persons with opioid use disorder (OUD). This study examined individual differences in opioid effects within an opioid-naïve population. To be presented… Read More

Durgin C, Huhn A, Bergeria C, Finan P, Campbell C, Antoine D, Dunn K. Only a percentage of people exposed to opioids develop problematic use. Individual opioid sensitivity may explain different opioid risk profiles, but to date has only been evaluated in persons with opioid use disorder (OUD). This study examined how opioid sensitivity manifests… Read More

June 19-23, 2023 | Denver, CO Jack Henningfield and Ryan Lanier will be attending. VIEW CONFERENCE

Moline ML, Cheng JY, Durgin C, Pype S, Buchhalter A, Henningfield J To identify differences and similarities in real-world abuse potential between dual orexin receptor antagonists (DORAs) and other drugs used as hypnotics, either Schedule IV (CIV) or unscheduled. DORAs, the newest hypnotic class, were placed in CIV based largely on human abuse potential (HAP)… Read More

June 17-21, 2023 | Denver, CO Judy Ashworth, Jack Henningfield, August Buchhalter, Ryan Lanier and Caitlyn Durgin will be attending. VIEW CONFERENCE WEBSITE Posters: Within-Subject Variations in Opioid Sensitivity Across Patient-reported Outcomes, Observer-Ratings, Physiological Endpoints, and Analgesic Responses A Novel 3 mg Naloxone Nasal Spray for the Over-the-Counter Market Abuse Potential Similarities Between Hypnotic Classes:… Read More

Ashworth J, Davis VG, Mannion R, Hufford M   To be presented at the 85th CPDD Annual Scientific Meeting, Poster Session 2, June 19, 2023.